Clarity Pharmaceuticals (ASX: CU6) has significantly bolstered its commercialisation strategy with a large-scale manufacturing supply agreement for its copper-64 isotope, a crucial component for its lead prostate cancer agent, 64Cu-SAR-bisPSMA.
Clarity has inked a large-scale manufacturing supply agreement with Theragenics that aims to ensure a robust supply chain for its novel radiopharmaceuticals.
Theragenics' facility near Atlanta, Georgia, is a substantial 134,000 square feet and features a fleet of 14 cyclotrons.
This capacity can support high-volume copper-64 (Cu-64) production, with each cyclotron capable of approximately 100Ci (3.7 TBq) of Cu-64 per day.
This translates to an estimated 2,000 patient doses per day per cyclotron at 200 MBq per dose.
Supporting 64Cu-SAR-bisPSMA Commercialisation
The agreement is a key step toward establishing a robust supply network ahead of the potential commercial launch of 64Cu-SAR-bisPSMA.
The product is currently undergoing Phase III registrational trials.
Clarity links this manufacturing strategy to its anticipated FDA NDA approval following the successful completion of its pivotal Phase III trials, AMPLIFY 1 and CLARIFY 2.
The company intends to support commercial-scale demand across multiple oncology indications.
The deal aims to avoid excessive costs, waste, and inefficiencies associated with supplying short half-life isotopes.
While copper-64 has a 12.7-hour half-life, 64Cu-SAR-bisPSMA offers an extended 48-hour shelf life, making it advantageous for distribution logistics.
Clinical Progress Continues
The Phase III AMPLIFY trial has exceeded its planned participant consent target, indicating strong demand across the US and Australia.
Recruitment for the trial commenced in May 2025 and reached its initial milestone within nine months.
Recent data from the Co-PSMA trial, presented at EAU 2026, showed 64Cu-SAR-bisPSMA outperformed standard-of-care imaging (68 Ga-PSMA-11 PET/CT) in detecting lesions.
In a head-to-head comparison involving 50 men with biochemical recurrence, 64Cu-SAR-bisPSMA identified more lesions and led to a management change in 44% of participants.
The SECuRE trial continues to provide supportive safety and efficacy data for 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer.
A fifth participant in the cohort expansion achieved undetectable PSA after the first cycle and a negative PSMA PET after the second cycle, with mild (Grade 1) adverse events reported.
Financials and Operational Landscape
Clarity reported a significant half-year loss of $55.6 million attributable to owners for the period ending December 31, 2025, with no revenue generated from ordinary activities.
This represented an increase of 136% compared to the prior half-year.
The company wound up Clarity Pharmaceuticals Europe SA on December 31, 2025, resulting in a loss of control and indicating a portfolio reorganisation as part of its operational streamlining efforts.
Despite the ongoing losses, net tangible assets per ordinary security increased to 62.6 cents from 39.7 cents in the previous half-year, providing some balance sheet support.
